Experimental remedy can reduce the chances of developing Alzheimer's disease

In a clinical study, encouraging results have revealed that an experimental means can reduce the risk of developing ‘Alzheimer’s’ in persons who were exposed to the disease in the early centuries, such as the thirties, forties or fifties. The results, published in the “The Lancet Neurology”, indicate that early treatment by “amyloid plaques” removed from the brain years before the symptoms appeared; It can at least prevent or delay the occurrence of dementia associated with Alzheimer’s disease. Alzheimer’s disease, one of the most common forms of dementia, is closely related to the accumulation of protein plates in the brain, known as ‘amyloid plaques’, and these plaques consist of a protein called ‘beta ammyloid’ that arises between nerve cells, which disrupts the communication and eventually. Scientists believe that the accumulation of these plaques is one of the early events in the course of the disease, where congestion begins years ago, and perhaps rally, from the rise of the first symptoms such as memory loss and problems with thinking. According to the “amyloid hypothesis”, which is the most accepted theory to understand Alzheimer’s disease, the accumulation of these plaques releases a series of complex biological events, including nerve inflammation, nervous fibroids and the loss of nerve connections, and eventually leads to the improvement of cognitive and behavioral functions. The new study included 73 people with rare genetic mutations inherited, leading to excessive production of amyloid in the brain, making them vulnerable to Alzheimer’s disease in the middle drug. In a branch of 22 participants, they showed no cognitive problems when the study began, and they received treatment for an average of eight years; The risk of developing their symptoms has dropped from 100% to about 50%, according to a preliminary data analysis, supported by various sensitivity analyzes confirming this trend. Alzheimer’s disease according to researchers; All participants in this study could develop Alzheimer’s disease, and some of them have not yet had symptoms. “We do not know how much time they will stay without symptoms, maybe a few years or maybe contracts … We have continued to treat them with other antibodies for the amyloid in the hope that they will never show symptoms, and what we know is that it is at least the appearance of the symptoms of Alzheimer’s, and that people have the effects of the effects of the study of the study, the Researchers have studied. Anti-Anti-drug for the Meufdoce to undergo. This treatment has been developed to stimulate the immune cells in the brain to remove these congestion, which helps improve mental functions and reduce the negative effects of the disease. “Jantineromab” depends on the injection of antibodies into the bloodstream, associated with abnormal protein groups in the brain, and after association with these lumps, the immune system stimulates their dismantling and removal, which helps reduce the damage to nerve cells. This treatment underwent several previous clinical trials, including studies at different stages of the disease, and initially experiments showed positive results, as the treatment reduced the amounts of proteins laid down in the brain, but with the progress of experiments, unexpected challenges emerged, including side effects associated with stroke or swelling in some cases. Despite these challenges, studies have continued on the possibility of adjusting or integrating treatment doses with other medicines to increase its effectiveness and reduce risks, and some clinical experiments have been discontinued after the rise of unive results, but researchers still study the effects of high doses on people in the early stages of the disease. The researchers used this treatment long before the symptoms appeared in patients; Participants in the experiment have taken small doses of the drug over the years. In the new clinical experience; The use of the trait is associated with side effects, known as the imaging disorders associated with amyloid, which includes the appearance of small bloody spots or a topical swelling in the brain. In this study, most cases were without symptoms, and it was automatically resolved, and the treatment was suspended for participants only; Due to the severity of the side effects, no life -threatening deaths or events occurred. The late Alzheimer’s, while the experiment focused on early Alzheimer’s genetic patients, expects researchers to help the results to prevent and treat all forms of the disease, including the late Alzheimer’s that starts in age, as studies indicate that both cases begin with the accumulation of “amyloid” in the brain to prevent the disregard of cognitive problems. Promising strategy occurs. And if the preventative experiences of Alzheimer’s delay show similar results to those of the clinical experience; There may soon be effective strategies to prevent disease among the general population. These results are the first clinical guide for the possibility of preventing Alzheimer’s, which can help millions of people in the future, and an expansion stage has been launched, and all participants received the experimental drug without a control group, and their results were compared to participants in another monitoring study who received no treatment. The results showed that the removal of ‘amyloid plaques’ years before the rise of symptoms resulted in the occurrence of dementia delayed, but the effect was only statistically significant in the group that received treatment for the longest period, which was on average eight years.